Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients withulcerative colitis

Inflammatory Bowel Diseases

Volumn 15, Issue 7, 2009, Pages 1062-1070

  Ferrante, Marc ^a   D'Hoore, A ^a   Vermeire, S ^a   Declerck, S ^a   Noman, M ^a   Van Assche, G ^a   Hoffman, I ^a   Rutgeerts, P ^a   Penninckx, F ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Corticosteroids; Infliximab; IPAA; Postoperative infectious complications; Pouch; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; INFLIXIMAB; METHYLPREDNISOLONE; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADULT; ANASTOMOSIS LEAKAGE; APPLICATION SITE INFECTION; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG HALF LIFE; DRUG MEGADOSE; FEMALE; HUMAN; ILEOSTOMY; LENGTH OF STAY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PELVIS ABSCESS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROCTOCOLECTOMY; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SHORT COURSE THERAPY; SMOKING; SURGICAL RISK; TREATMENT DURATION; ULCERATIVE COLITIS; WOUND INFECTION; ABDOMINAL ABSCESS; IMMUNE DEFICIENCY; IMMUNOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PREDICTION AND FORECASTING; RISK FACTOR; STATISTICS; SURGICAL INFECTION;

ABDOMINAL ABSCESS; ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; LENGTH OF STAY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROCTOCOLECTOMY, RESTORATIVE; RISK FACTORS; SURGICAL WOUND INFECTION;

EID: 69449087793     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20863     Document Type: Article

References (25)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
2. Baumgart DC, Sandborn WJ. Gastroenterology 2 - inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657.
3. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
4. Langholz E, Munkholm P, Davidsen M, et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology. 1992;103: 1444-1451.
5. Melville DM, Ritchie JK, Nicholls RJ, et al. Surgery for ulcerative colitis in the era of the pouch: the St Mark's Hospital experience. Gut. 1994;35:1076-1080.
6. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995;222:120-127.
7. Brzezinski A, Armstrong L, Del Real GA, et al. Infliximab does not increase the risk of complications in the perioperative period in patients with Crohn's disease. Gastroenterology. 2002;122:A617.
8. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99:878-883.
9. Marchal L, D'Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther. 2004;19:749-754.
10. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204:956-962.
11. Mor IJ, Vogel JD, da Luz Moreira A, et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum. 2008;51: 1202ndash;1207.
12. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6.
13. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
14. Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther. 2001;15:463-473.
15. Heyvaert G, Penninckx F, Filez L, et al. Restorative proctocolectomy in elective and emergency cases of ulcerative colitis. Int J Colorectal Dis. 1994;9:73-76.
16. Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut. 2004;53:780-782.
17. Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg. 2008;12:1730-1736.
18. Giles JT, Bartlett SJ, Gelber AC, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum. 2006;55:333-337.
19. Ruyssen-Witrand A, Gossec L, Salliot C, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol. 2007;25:430-436.
20. den Broeder AA, Creemers MC, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol. 2007;34:689-695.
21. Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum. 2007;50:1747-1753.
22. Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg. 2008;12:1738-1744.
23. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
24. D'Haens G, Colombel JF, Hornmes DW, et al. Corticosteroids pose an increased risk for serious infection: an interim safety analysis of the ENCORE registry. Gastroenterology. 2008;134:A140.
25. Subramanian V, Saxena S, Kang JY, Pollok RC. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol. 2008;103:2373-2381.